BRPI0413404A - composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif - Google Patents

composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif

Info

Publication number
BRPI0413404A
BRPI0413404A BRPI0413404-4A BRPI0413404A BRPI0413404A BR PI0413404 A BRPI0413404 A BR PI0413404A BR PI0413404 A BRPI0413404 A BR PI0413404A BR PI0413404 A BRPI0413404 A BR PI0413404A
Authority
BR
Brazil
Prior art keywords
methods
treating
effective amount
therapeutically effective
pharmaceutical compositions
Prior art date
Application number
BRPI0413404-4A
Other languages
English (en)
Inventor
Brett Giroir
Monte Willis
Vidal De La Cruz
Thais Sielecki
Original Assignee
Cytokine Pharmasciences Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc, Univ Texas filed Critical Cytokine Pharmasciences Inc
Publication of BRPI0413404A publication Critical patent/BRPI0413404A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

"COMPOSIçõES FARMACêUTICAS, MéTODOS DE TRATAMENTO OU PREVENçãO DE DISFUNçõES CARDìACAS, MéTODOS DE AUMENTO DA FUNçãO CARDìACA E MéTODO DE IDENTIFICAçãO DE INIBIDOR DE MIF". Uma realização da presente invenção refere-se a uma composição farmacêutica, que inclui quantidade terapeuticamente eficaz de pelo menos um anticorpo anti-MIF; e pelo menos um veículo farmaceuticamente aceitável. Outra realização da presente invenção refere-se a uma composição farmacêutica, que inclui quantidade terapeuticamente eficaz de pelo menos um anticorpo anti-CD74; e pelo menos um veículo farmaceuticamente aceitável. Outra realização da presente invenção refere-se a uma composição farmacêutica, que inclui quantidade terapeuticamente eficaz de pelo menos um anticorpo anti-TNFR; quantidade terapeuticamente eficaz de pelo menos um anticorpo anti-MIF; e pelo menos um veículo farmaceuticamente aceitável. Outras realizações da presente invenção referem-se a métodos de tratamento ou prevenção de disfunções cardíacas, cardiodepressão, disfunções cardíacas associadas a lesões por queimas, melhoria da função cardíaca em pacientes após enfarte agudo do miocárdio e identificação de inibidor de MIF.
BRPI0413404-4A 2003-08-29 2004-08-30 composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif BRPI0413404A (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49865903P 2003-08-29 2003-08-29
US54705404P 2004-02-25 2004-02-25
US54705904P 2004-02-25 2004-02-25
US54705604P 2004-02-25 2004-02-25
US54705704P 2004-02-25 2004-02-25
US55644004P 2004-03-26 2004-03-26
US10/927,494 US20050202010A1 (en) 2003-08-29 2004-08-27 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
PCT/US2004/027945 WO2005020919A2 (en) 2003-08-29 2004-08-30 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor

Publications (1)

Publication Number Publication Date
BRPI0413404A true BRPI0413404A (pt) 2006-10-17

Family

ID=34280266

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413404-4A BRPI0413404A (pt) 2003-08-29 2004-08-30 composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif

Country Status (15)

Country Link
US (3) US20050202010A1 (pt)
EP (2) EP1658037B1 (pt)
JP (3) JP4891769B2 (pt)
CN (2) CN102499984B (pt)
AU (1) AU2004268017B2 (pt)
BR (1) BRPI0413404A (pt)
CA (1) CA2537928C (pt)
CY (1) CY1117925T1 (pt)
DK (1) DK1658037T3 (pt)
ES (1) ES2599032T3 (pt)
HU (1) HUE029888T2 (pt)
MX (2) MXPA06001828A (pt)
PL (1) PL1658037T3 (pt)
PT (1) PT1658037T (pt)
WO (1) WO2005020919A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
MXPA06010793A (es) * 2004-03-26 2006-12-19 Cytokine Pharmasciences Inc Compuestos composiciones, procesos de elaboracion, y metodos de uso relacionados a la inhibicion del factor inhibidor de migracion de macrofago.
EP1819731A4 (en) * 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
WO2006116688A2 (en) * 2005-04-26 2006-11-02 Yale University Mif agonists and antagonists and therapeutic uses thereof
KR20110014141A (ko) * 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
WO2010065491A2 (en) * 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
WO2013023233A1 (en) * 2011-08-12 2013-02-21 Alfred Health Method for diagnosis, prognosis or treatment of acute coronary syndrome (acs) comprising measurement of plasma concentration of macrophage migration inhibitory factor (mif)
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
JP2016502669A (ja) * 2012-12-07 2016-01-28 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 抗ｍｉｆ抗体細胞遊走アッセイ
CN105087610A (zh) * 2015-09-11 2015-11-25 中国科学院海洋研究所 文蛤巨噬细胞迁移抑制因子基因及其编码蛋白和应用
JP2018007029A (ja) * 2016-07-01 2018-01-11 株式会社村田製作所 バイアス回路
EP4334469A1 (en) * 2021-05-06 2024-03-13 Abbott Molecular Inc. Compositions and methods for simple sample extraction
CN114288387A (zh) * 2022-02-17 2022-04-08 重庆医科大学 Humanin衍生物HNG在制备治疗心衰药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080407A (en) 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
DK1028738T3 (da) * 1997-11-05 2003-08-11 Univ Southern California Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser
JP2003513065A (ja) 1999-10-29 2003-04-08 ザ・ピコワー・インスティチュート・フォー・メディカル・リサーチ Ｍｉｆアンタゴニスト活性を有する化合物
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
AU2001238677A1 (en) * 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DE60236921D1 (de) * 2001-03-29 2010-08-19 Cytokine Pharmasciences Inc Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
AU2002314944B2 (en) * 2001-06-08 2008-03-06 Cytokine Pharmasciences, Inc. Isoxazoline compounds having MIF antagonist activity
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor

Also Published As

Publication number Publication date
CA2537928C (en) 2015-05-05
JP2010159267A (ja) 2010-07-22
CY1117925T1 (el) 2017-05-17
EP3078386A3 (en) 2017-01-11
EP3078386A2 (en) 2016-10-12
WO2005020919A2 (en) 2005-03-10
PT1658037T (pt) 2016-08-30
US20080260723A1 (en) 2008-10-23
US8747843B2 (en) 2014-06-10
AU2004268017B2 (en) 2011-03-17
EP1658037A2 (en) 2006-05-24
PL1658037T3 (pl) 2017-08-31
JP2007504158A (ja) 2007-03-01
CN1972713B (zh) 2012-02-29
MX340217B (es) 2016-06-30
MXPA06001828A (es) 2007-05-23
AU2004268017A2 (en) 2005-03-10
JP5905659B2 (ja) 2016-04-20
JP4891769B2 (ja) 2012-03-07
AU2004268017A1 (en) 2005-03-10
CA2537928A1 (en) 2005-03-10
HUE029888T2 (en) 2017-04-28
CN1972713A (zh) 2007-05-30
ES2599032T3 (es) 2017-01-31
US20050202010A1 (en) 2005-09-15
CN102499984A (zh) 2012-06-20
DK1658037T3 (en) 2016-08-29
EP1658037B1 (en) 2016-05-25
WO2005020919A3 (en) 2006-11-30
EP1658037A4 (en) 2008-09-10
CN102499984B (zh) 2015-02-18
US20150017179A1 (en) 2015-01-15
JP2011251966A (ja) 2011-12-15

Similar Documents

Publication Publication Date Title
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
MXPA02012434A (es) Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
BR0200155A (pt) Tratamento combinado para depressão
BR0310092A (pt) Combinação de compostos orgânicos
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR9914419A (pt) Terapia para melhoria da percepção
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE SEU ARQUIVAMENTO NOTIFICADO NA RPI NO 2226 DE 03/09/2013 (DESPACHO 11.5), DE ACORDO COM O ART. 34 DA LPI. NO ENTANTO, O REQUERENTE ATENDEU AOS PRESSUPOSTOS DO ART. 34 DA LPI, TEMPESTIVAMENTE, ATRAVES DA PETICAO NO DESP 018120015381 DE 03/05/2012 (DECLARACAO NEGATIVA). DESTE MODO, ANULO O REFERIDO ARQUIVAMENTO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (U

B25A Requested transfer of rights approved

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) ; BAXTER INTERNATIONAL, INC. (US) ; BAXTER INTERNATIONAL, INC. (CH)

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (U

B25C Requirement related to requested transfer of rights

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) ; BAXTER INTERNATIONAL, INC. (US) ; BAXTER INTERNATIONAL, INC. (CH)

Free format text: A FIM DE ATENDER AS TRANSFERENCIAS, REQUERIDAS ATRAVES DA PETICAO NO 870180073210, DE21/08/2018, E NECESSARIO APRESENTAR DUAS GRU'S, UMA PARA CADA SERVICO, TENDO EM VISTA SEREMDUAS TRANSFERENCIAS DE TITULARIDADE SOLCIITADAS E APENAS A GRU DE NUMERO 29409161808130188FOI APRESENTADA PARA TAIS FINALIDADES.

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (U

Free format text: A FIM DE ATENDER AS TRANSFERENCIAS, REQUERIDAS ATRAVES DA PETICAO NO 870180073210, DE21/08/2018, E NECESSARIO APRESENTAR DUAS GRU'S, UMA PARA CADA SERVICO, TENDO EM VISTA SEREMDUAS TRANSFERENCIAS DE TITULARIDADE SOLCIITADAS E APENAS A GRU DE NUMERO 29409161808130188FOI APRESENTADA PARA TAIS FINALIDADES.

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (U

Free format text: RETIFICACAO DO DESPACHO ?(25.1) - TRANSFERENCIA DEFERIDA? PUBLICADO NA RPI NO 2505 DE 08/01/2019, QUANTO AO ITEM (71):ONDE SE LE: ?BAXTER INTERNATIONAL, INC.? LEIA-SE: ?BAXTER HEALTHCARE SA?

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (U

Free format text: RETIFICACAO DO DESPACHO ?(25.3) - TRANSFERENCIA EM EXIGENCIA? PUBLICADO NA RPI NO 2505, DE 08/01/2019:ONDE SE LE: ?A FIM DE ATENDER AS TRANSFERENCIAS, REQUERIDAS ATRAVES DA PETICAO NO870180073210, DE 21/08/2018, E NECESSARIO APRESENTAR DUAS GRU'S, UMA PARA CADA SERVICO,TENDO EM VISTA SEREM DUAS TRANSFERENCIAS DE TITULARIDADE SOLCIITADAS E APENAS A GRU DE NUMERO29409161808130188 FOI APRESENTADA PARA TAIS FINALIDADES.? LEIA-SE: ?A FIM DE ATENDER AS TRANSFERENCIAS REQUERIDAS ATRAVES DA PETICAO NO870180073208 DE 21/08/2018, E NECESSARIO APRESENTAR DUAS GRU'S, UMA PARA CADA SERVICO,TENDO EM VISTA SEREM DUAS TRANSFERENCIAS DE TITULARIDADE SOLICITADAS

B25A Requested transfer of rights approved

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (U

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) ; BAXALTA INCORPORATED (US) ; BAXALTA GMBH (CH)

B25G Requested change of headquarter approved

Owner name: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (U

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]